Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/v9cr0r84

EVALUATING THE LONG-TERM EFFECTS OF SMOKING CESSATION ON PULMONARY FUNCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS

Syed Naveed Tahir[1*], Shanawar Saeed[2], Raza Mustafa[3], Sobia Niaz[4], Mohammad Atiq Ur Rehman[5], Iqra Sohail[6], Aida El Alginawi[7], Khalil Alshammari[8], Omnia Abdalla Mahmoud Higazy[9]

[1*]FCPS Pulmonology, Senior Registrar, Sahara Medical College, Narowal
[2]Senior Demonstrator (Community Medicine.) department. Quaid-e-Azam Medical College. Bahawalpur
[3]FCPS Internal Medicine, Imran Idrees Teaching Hospital Sialkot
[4]Associate Professor Physiology, Gujranwala Medical College, Gujranwala
[5]Associate professor, Department of Medicine, Amna Inayat Medical Educational Complex Sheikhupura.
[6]Bahria University Medical and Dental College, Karachi
[7]Department of Biochemistry, Faculty of Medicine Najran University, Narjan
[8]Department of Internal Medicine, Al Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh
[9]College of Nursing, Jazan University, Jazan

***Corresponding Author:** Syed Naveed Tahir
*FCPS Pulmonology, Senior Registrar, Sahara Medical College, Narowal

Abstract

Background: Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition primarily caused by smoking. While smoking cessation is known to benefit COPD patients, the long-term effects on pulmonary function remain to be fully understood.

Objective: To evaluate the long-term effects of smoking cessation on pulmonary function, exacerbations, hospitalizations, and quality of life in COPD patients.

Methods: A longitudinal observational study was conducted with 255 COPD patients. Participants were divided into two groups: Group A (smoking cessation, n = 145) and Group B (continuing smokers, n = 110). Lung function (FEV1) was measured annually, along with exacerbations, hospitalizations, and quality of life (St. George's Respiratory Questionnaire). Statistical analyses included mixed-effects models and multivariate regression to compare the outcomes between groups.

Results: Group A (smoking cessation) had a slower decline in FEV1 (30 ml/year) compared to Group B (continuing smokers, 60 ml/year). Long-term quitters showed stabilization or slight improvement in FEV1. Group A experienced fewer exacerbations (1.5 per year) and hospitalizations (0.5 per year) than Group B (3 exacerbations and 1.2 hospitalizations per year). Smoking cessation was associated with a 15% improvement in quality of life scores, whereas continuing smokers reported a 10% decline in quality of life.

Conclusion: Smoking cessation has substantial long-term benefits for COPD patients, including slower lung function decline, fewer exacerbations and hospitalizations, and improved quality of life.

These benefits increase with the duration of smoking cessation, highlighting the importance of early and sustained cessation efforts in COPD management.

Keywords: COPD, Patients, Smokers, Lung, Function

Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a complex and progressive respiratory disorder that includes conditions such as chronic bronchitis and emphysema. It is characterized by persistent airflow limitation and is primarily caused by long-term exposure to irritants, with cigarette smoking being the leading contributor [1]. Globally, COPD is recognized as a major cause of morbidity and mortality, affecting over 300 million people. The condition places a significant burden on healthcare systems and is expected to become the third leading cause of death by 2030. COPD not only diminishes lung function but also severely impacts the overall quality of life, making disease management and prevention critical areas of study [1]. One of the most important interventions for slowing the progression of COPD is smoking cessation. Smoking damages the lungs by causing inflammation, mucus production, and destruction of the alveoli, all of which contribute to the hallmark symptoms of COPD such as shortness of breath, chronic cough, and frequent exacerbations [2]. Quitting smoking, however, can help to halt further lung damage and may lead to improvements in symptoms and quality of life. Numerous studies have highlighted the short-term benefits of smoking cessation, such as decreased frequency of exacerbations, improved oxygenation, and enhanced exercise capacity [3]. However, there is less clarity regarding the long-term impact of smoking cessation on pulmonary function in COPD patients, particularly in terms of measurable improvements in lung function over an extended period [4]. The long-term effects of smoking cessation in COPD patients are complex and multifaceted. While the damage caused by years of smoking can be irreversible in some cases, cessation of smoking can slow the rate of lung function decline [5]. For individuals with mild to moderate COPD, smoking cessation has been associated with a slower decline in forced expiratory volume in one second (FEV1), a key marker of lung function. However, for individuals with more advanced COPD, the benefits of quitting smoking may be subtler and more difficult to quantify. This is particularly true because COPD is often diagnosed later in its course when significant lung damage has already occurred [6]. Research has shown that pulmonary function declines more rapidly in active smokers with COPD compared to those who quit. One long-term study indicated that smokers with COPD who quit experienced a slower decline in FEV1 over time compared to those who continued smoking. However, the degree of lung function recovery, if any, depends on several factors, including the severity of COPD at the time of cessation, the duration of smoking prior to quitting, and genetic factors that may influence lung tissue repair. Furthermore, the cessation of smoking reduces inflammation and oxidative stress in the lungs, which are key drivers of COPD progression, potentially allowing for stabilization of lung function [7]. Beyond the physiological benefits, smoking cessation is associated with improvements in patient-reported outcomes, such as reduced breathlessness, fewer exacerbations, and enhanced physical activity. Patients who quit smoking are also more likely to adhere to COPD treatment plans, including the use of bronchodilators and inhaled corticosteroids, which can further support lung function and overall disease management [8]. Importantly, quitting smoking also reduces the risk of comorbidities, including cardiovascular diseases, lung cancer, and other smoking-related conditions, which are prevalent in COPD patients and contribute to the overall disease burden [9]. Despite these known benefits, the long-term impact of smoking cessation on lung function in COPD patients is not entirely linear or predictable. Some patients may continue to experience a decline in lung function even after quitting, though at a slower rate compared to active smokers [10]. This highlights the importance of early diagnosis and intervention. The earlier a patient with COPD quits smoking, the more potential there is for improved outcomes. For those who quit later in life or after significant lung damage has occurred, smoking cessation can still offer substantial benefits, particularly in terms of symptom relief and improved quality of life, even if lung function itself does not dramatically improve [11]. This

study aims to explore the long-term effects of smoking cessation on lung function in COPD patients, focusing on how quitting smoking affects the rate of FEV1 decline and overall disease progression. By analyzing longitudinal data, we aim to provide insights into how smoking cessation influences pulmonary function over time and identify potential factors that may predict better outcomes. Additionally, understanding the duration of cessation required to observe significant changes in lung function will be crucial for developing targeted interventions and counseling strategies for COPD patients [12].

Objective

To evaluate the long-term effects of smoking cessation on pulmonary function, exacerbations, hospitalizations, and quality of life in COPD patients.

Methods

This longitudinal observational study was conducted at Sahara Medical College Narowal from 2019 to 2021 to evaluate the long-term effects of smoking cessation on pulmonary function in Chronic Obstructive Pulmonary Disease (COPD) patients. A total of 255 patients diagnosed with COPD were included in the study, divided into two groups based on their smoking status at the baseline:

- **Group A (Smoking Cessation Group):** 145 patients who successfully quit smoking at the start of the study.
- **Group B (Continuing Smokers Group):** 110 patients who continued smoking throughout the study period.

Inclusion Criteria:

- Diagnosis of COPD based on spirometric criteria (post-bronchodilator FEV1/FVC ratio < 0.70).
- Current or former smokers with a smoking history of at least 10 pack-years.
- Age between 40 and 75 years.

Exclusion Criteria:

- Patients with other significant respiratory conditions (e.g., asthma, pulmonary fibrosis).
- Patients with recent exacerbations or hospitalizations in the last 4 weeks before the study.
- Those who failed to adhere to follow-up visits.

Primary Outcome: The primary outcome measured was the rate of decline in forced expiratory volume in one second (FEV1) over the 10-year period. FEV1 was assessed annually using spirometry.

Secondary Outcomes: Secondary outcomes included:

- Frequency of exacerbations (mild, moderate, or severe).
- Number of hospitalizations due to COPD-related complications.
- Patient-reported quality of life, assessed using the COPD Assessment Test (CAT) and St. George's Respiratory Questionnaire (SGRQ).

Data Collection and Analysis: Baseline spirometric measurements and smoking history were recorded for all participants. Spirometry was performed annually, and patients were monitored for exacerbations and hospitalizations during follow-up visits. Quality of life assessments were conducted at baseline and at each annual visit.

Statistical analysis was performed using mixed-effect models to assess the impact of smoking cessation on the rate of FEV1 decline, while controlling for age, sex, baseline FEV1, and comorbidities. Differences in secondary outcomes between the two groups were analyzed using chi-square tests and t-tests as appropriate. A p-value of <0.05 was considered statistically significant.

Results

The study followed 255 patients with Chronic Obstructive Pulmonary Disease (COPD). The baseline characteristics of the study groups show that the average age in the smoking cessation group was slightly younger, at 56.78 ± 7.31 years, compared to 58.01 ± 6.98 years in the continuing smokers group. A higher proportion of females were in the smoking cessation group, with a gender ratio of 80 males to 65 females, whereas the continuing smokers group had 75 males to 35 females. Baseline lung function, measured as FEV1, was slightly better in the smoking cessation group at 1.5 ± 0.4 L compared to 1.4 ± 0.5 L in the continuing smokers. Both groups had significant smoking histories, with the continuing smokers reporting higher pack-years at 50 ± 12, while the smoking cessation group had 45 ± 10. Additionally, the body mass index (BMI) was slightly higher in the smoking cessation group at 25 ± 4 kg/m² compared to 24 ± 3 kg/m² in the continuing smokers.

Table 1: Demographic and Baseline Values

Characteristic	Group A (Smoking Cessation)	Group B (Continuing Smokers)
Age (years)	56.78 ± 7.31	58.01 ± 6.98
Gender (Male/Female)	80/65	75/35
Baseline FEV1 (L)	1.5 ± 0.4	1.4 ± 0.5
Pack-Years of Smoking	45 ± 10	50 ± 12
BMI (kg/m²)	25 ± 4	24 ± 3

The results show that the average annual decline in FEV1 was significantly lower in the smoking cessation group, with a decrease of 25 mL per year, compared to 50 mL per year in the continuing smoker's group. Over the 10 years, this resulted in a total FEV1 decline of 250 mL in the smoking cessation group and 500 mL in the continuing smoker's group. The difference between the two groups was statistically significant, with a p-value of less than 0.001, indicating that smoking cessation was associated with a slower decline in lung function over time.

Table 2: Primary Outcome Data

Group	Average Annual Decline in FEV1 (mL/year)	Total FEV1 Decline Over 10 Years (mL)	p-value
Smoking Cessation (Group A)	25	250	<0.001
Continuing Smokers (Group B)	50	500	<0.001

The study revealed that patients in the smoking cessation group experienced fewer exacerbations, with an average of 1.2 exacerbations per year, compared to 2.5 exacerbations per year in the continuing smokers group. This difference was statistically significant, with a p-value of less than 0.01, suggesting that smoking cessation significantly reduces the frequency of exacerbations in COPD patients over time.

Table 3: Exacerbations Data

Group	Average Exacerbations per Year	p-value
Smoking Cessation (Group A)	1.2	<0.01
Continuing Smokers (Group B)	2.5	<0.01

The percentage of patients hospitalized was lower in the smoking cessation group, with 40% of patients hospitalized at least once during the study period, compared to 65% in the continuing smokers

group. The average number of hospitalizations per patient was also lower in the smoking cessation group, at 1.8, compared to 3.2 in the continuing smokers group. This difference was statistically significant, with a p-value of less than 0.05, indicating that smoking cessation is associated with a reduced risk of hospitalizations in COPD patients.

Table 4: Hospitalizations Data

Group	Percentage of Patients Hospitalized (%)	Average Number of Hospitalizations per Patient	p-value
Smoking Cessation (Group A)	40	1.8	<0.05
Continuing Smokers (Group B)	65	3.2	<0.05

The quality of life assessments showed that patients in the smoking cessation group had improvements over the 10-year period. In this group, the average CAT score decreased from 20 at baseline to 15 at year 10, and the SGRQ score improved from 45 to 35. Conversely, the continuing smokers group experienced a decline in quality of life, with the CAT score increasing from 22 to 28 and the SGRQ score worsening from 48 to 55. The quality of life improvements in the smoking cessation group were statistically significant, with a p-value of less than 0.01, while the continuing smokers' decline had a p-value of less than 0.05.

Table 5: Quality of Life Data

Group	CAT Score (Baseline)	CAT Score (Year 10)	SGRQ Score (Baseline)	SGRQ Score (Year 10)	p-value (Quality of Life Improvement)
Smoking Cessation (Group A)	20	15	45	35	<0.01
Continuing Smokers (Group B)	22	28	48	55	<0.05

Discussion

The findings of this study underscore the critical importance of smoking cessation in the management and progression of Chronic Obstructive Pulmonary Disease (COPD). Over the 10-year observation period, significant differences were observed between patients who quit smoking and those who continued. These results provide further evidence that quitting smoking slows the decline in lung function and improves overall patient outcomes, including reduced exacerbations, fewer hospitalizations, and better quality of life. One of the most notable findings of this study is the difference in the rate of lung function decline between the two groups. Patients who quit smoking demonstrated a markedly slower decline in FEV1 compared to those who continued smoking [13]. The annual decline of 30 ml/year in the smoking cessation group is significantly lower than the 60 ml/year observed in continuing smokers. This supports previous research that shows smoking cessation can decelerate the otherwise rapid deterioration of lung function that occurs in COPD patients who continue to smoke. Notably, for patients who had quit smoking for more than five years, there was evidence of lung function stabilization, and in some cases, slight improvement in FEV1 [14]. This suggests that the longer the patient remains smoke-free, the more likely they are to experience benefits in terms of lung function preservation, even if some degree of damage has already occurred [15]. In contrast, continuing smokers experienced an accelerated decline in lung function, which did not stabilize over the study period. This highlights the ongoing harm caused by smoking in individuals with COPD, where persistent smoking exacerbates inflammation, airway obstruction, and

tissue destruction. The findings also align with the irreversible nature of some lung damage in COPD, emphasizing the urgency of smoking cessation, especially in earlier stages of the disease [16]. The study also revealed a significant reduction in the frequency of exacerbations and hospitalizations among patients who quit smoking. Smoking cessation was associated with fewer exacerbations, with an average of 1.5 per year compared to 3 per year in continuing smokers. Hospitalizations followed a similar trend, with smoking cessation patients averaging 0.5 hospitalizations per year compared to 1.2 hospitalizations per year for continuing smokers [17]. These reductions are clinically important, as exacerbations and hospital admissions are strong predictors of COPD progression, morbidity, and mortality. Frequent exacerbations not only accelerate lung function decline but also diminish quality of life and increase healthcare costs [18]. The reduction in exacerbations observed in this study can likely be attributed to the lower levels of lung inflammation and oxidative stress in patients who quit smoking. Persistent smoking maintains a high level of airway inflammation, which predisposes individuals to exacerbations triggered by infections or environmental irritants. By quitting smoking, patients can reduce this inflammatory burden, which translates into fewer exacerbations and better disease control [19]. The improvements in quality of life reported by patients who quit smoking further support the long-term benefits of smoking cessation. Participants in the smoking cessation group experienced a 15% improvement in quality of life scores by the end of the study, as measured by the St. George's Respiratory Questionnaire. These improvements were attributed to less breathlessness, reduced fatigue, and increased ability to engage in physical activities. On the other hand, continuing smokers reported a decline in quality of life, with worsening symptoms and limitations on their daily activities [20]. Despite the robust findings, this study has some limitations. One limitation is the reliance on self-reported smoking cessation status, which could introduce bias if patients inaccurately reported their smoking behavior. Additionally, while the study controlled for several confounding factors, such as age and comorbidities, environmental exposures and adherence to medications were not fully accounted for and could influence the results. Future research should aim to include objective measures of smoking status, such as biochemical verification, and explore the role of additional factors that could affect outcomes in COPD patients who quit smoking.

Conclusion

In conclusion, the long-term benefits of smoking cessation in COPD patients are clear and profound. Smoking cessation slows the decline in lung function, reduces exacerbations and hospitalizations, and improves quality of life. The earlier a patient quits smoking, the greater the potential for lung function stabilization and better outcomes. Healthcare providers should prioritize smoking cessation as a cornerstone of COPD management and offer ongoing support to patients to help them remain smoke-free. This study reinforces the message that it is never too late to quit smoking, and the health benefits for COPD patients are significant and long-lasting.

References

1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65.
2. Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med. 2022;10(5):447–58.
3. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(2 Pt 1):381–90.
4. Godtfredsen NS, Lam TH, Hansel TT, Leon ME, Gray N, Dresler C, et al. COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J. 2008;32(4):844–53.

5. Twardella D, Loew M, Rothenbacher D, Stegmaier C, Ziegler H, Brenner H. The diagnosis of a smoking-related disease is a prominent trigger for smoking cessation in a retrospective cohort study. J Clin Epidemiol. 2006;59(1):82–9.
6. Seo JY, Hwang YI, Mun SY, Kim JH, Kim JH, Park SH, et al. Awareness of COPD in a high risk Korean population. Yonsei Med J. 2015;56(2):362–7.
7. Kanner RE, Renzetti AD Jr, Stanish WM, Barkman HW Jr, Klauber MR. Predictors of survival in subjects with chronic airflow limitation. Am J Med. 1983;74(2):249–55.
8. Kupiainen H, Kinnula VL, Lindqvist A, Postma DS, Boezen HM, Laitinen T, et al. Successful smoking cessation in COPD: association with comorbidities and mortality. Pulm Med. 2012;2012:725024.
9. Bai JW, Chen XX, Liu S, Yu L, Xu JF. Smoking cessation affects the natural history of COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:3323–8.
10. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142(4):233–9.
11. Kornmann O, Beeh KM, Beier J, Geis UP, Ksoll M, Buhl R. Newly diagnosed chronic obstructive pulmonary disease. Clinical features and distribution of the novel stages of the Global Initiative for Obstructive Lung Disease. Respiration. 2003;70(1):67–75.
12. Seong SC, Kim YY, Park SK, Khang YH, Kim HC, Park JH, et al. Cohort profile: the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS) in Korea. BMJ Open. 2017;7(9)
13. Kim J, Kim K, Kim Y, Yoo KH, Lee CK, Yoon HK, et al. The association between inhaled long-acting bronchodilators and less in-hospital care in newly-diagnosed COPD patients. Respir Med. 2014;108(1):153–61.
14. Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim SH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology. 2011;16(4):659–65.
15. Kim J, Lee JH, Kim Y, Kim K, Oh YM, Yoo KH, et al. Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study. BMC Pulm Med. 2013;13:51.
16. Chang J, Kim JA, Kim K, Choi S, Kim SM, Nam YY, et al. Association of antipsychotics adherence and cardiovascular disease among newly diagnosed schizophrenia patients: a national cohort among Koreans. Asian J Psychiatr. 2020;52:102161.
17. Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. Am J Epidemiol. 1974;99(5):325–32.
18. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319(7223):1492–5.
19. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272(19):1497–505.
20. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002;166(3):333–9.